Jazz Pharmaceuticals JAZZ Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.44B+4.0% | $4.27B+2.6% | $4.16B+1.7% | $4.09B+0.5% | $4.06B-0.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.65B-8.9% | $1.81B+2.1% | $1.77B+13.1% | $1.57B+1.3% | $1.55B+11.7% | ||
| $4.48B-4.7% | $4.7B+1.0% | $4.65B+6.3% | $4.38B+26.2% | $3.47B+3.5% | ||
| —— | —— | -$494.01M-69.6% | -$291.31M-149% | $594.52M-17.0% | ||
| $262.36M+5.6% | $248.56M-29.4% | $352.02M+3.0% | $341.9M+4.5% | $327.24M+3.9% | ||
| —— | —— | -$11.17M-2.9% | -$10.85M-440% | $3.2M+118% | ||
| —— | —— | -$703.1M-37.5% | -$511.33M-241% | $362.15M-23.0% | ||
| -$253.49M+8.6% | -$277.39M+17.3% | -$335.31M-212% | -$107.42M+11.2% | -$120.9M-32.2% | ||
| —— | —— | -$368.44M+9.0% | -$404.8M-184% | $482.24M-13.9% | ||
| —— | —— | -$6.16+9.7% | -$6.82-192% | $7.41-14.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Jazz Pharmaceuticals's revenue?
- Jazz Pharmaceuticals (JAZZ) generated $4.4B in revenue over the trailing twelve months, up 9.2% year over year.
- Is Jazz Pharmaceuticals profitable?
- Jazz Pharmaceuticals is not currently profitable: it reported a net loss of $266.5M over the trailing twelve months, a -8.9% net margin.
- What is Jazz Pharmaceuticals's earnings per share?
- Jazz Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.75.
- Where does Jazz Pharmaceuticals's income statement data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
